These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36660350)

  • 1. Glucose Homeostasis and Assessment of β-Cell Function by 3-hour Oral Glucose Tolerance (OGTT) in Patients with β-Thalassemia Major with Serum Ferritin below 1,000 ng/dL: Results from a Single ICET-A Centre.
    de Sanctis V; Soliman AT; Daar S; Tzoulis P; Di Maio S; Kattamis C
    Mediterr J Hematol Infect Dis; 2023; 15(1):e2023006. PubMed ID: 36660350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal study of ICET-A on glucose tolerance, insulin sensitivity and β-cell secretion in eleven β-thalassemia major patients with mild iron overload.
    De Sanctis V; Soliman AT; Daar S; Tzoulis P; Di Maio S; Kattamis C
    Acta Biomed; 2023 Feb; 94(1):e2023011. PubMed ID: 36786253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of isolated hyperglycemia (blood glucose ≥155 mg/dL) at 1-hour of oral glucose tolerance test (OGTT) in patients with β-transfusion dependent thalassemia (β-TDT) followed for 12 years.
    De Sanctis V; Soliman A; Tzoulis P; Daar S; Pozzobon GC; Kattamis C
    Acta Biomed; 2021 Sep; 92(4):e2021322. PubMed ID: 34487089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose Metabolism and Insulin Response to Oral Glucose Tolerance Test (OGTT) in Prepubertal Patients with Transfusion-Dependent β-thalassemia (TDT): A Long-Term Retrospective Analysis.
    De Sanctis V; Soliman AT; Tzoulis P; Daar S; Di Maio S; Fiscina B; Kattamis C
    Mediterr J Hematol Infect Dis; 2021; 13(1):e2021051. PubMed ID: 34527203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indicators of glucose dysregulation and the relationship with iron overload in Chinese children with beta thalassemia major.
    Zhang L; Meng Z; Jiang Z; Liu Z; Hou L; Cai G; Ou H; Huang S; Song Q; Fang J; Liang L
    Pediatr Diabetes; 2022 Aug; 23(5):562-568. PubMed ID: 34453777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe Liver Iron Concentrations (LIC) in 24 Patients with β-Thalassemia Major: Correlations with Serum Ferritin, Liver Enzymes and Endocrine Complications.
    Kanbour I; Chandra P; Soliman A; De Sanctis V; Nashwan A; Abusamaan S; Moustafa A; Yassin MA
    Mediterr J Hematol Infect Dis; 2018; 10(1):e2018062. PubMed ID: 30416694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final adult height and endocrine complications in young adults with β-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC.
    Soliman AT; Yassin MA; De Sanctis V
    Acta Biomed; 2018 Feb; 89(2-S):27-32. PubMed ID: 29451226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolution of glucose-insulin homeostasis in children with β-thalassemia major (β -TM): A twenty-year retrospective ICET- A observational analysis from early childhood to young adulthood.
    De Sanctis V; Daar S; Soliman AT; Tzoulis P; Karimi M; Kattamis C
    Acta Biomed; 2022 Jul; 93(3):e2022243. PubMed ID: 35775765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Follow-up of β-Transfusion-Dependent Thalassemia (TDT) Normoglycemic Patients with Reduced Insulin Secretion to Oral Glucose Tolerance Test (OGTT): A Pilot Study.
    de Sanctis V; Soliman AT; Daar S; Tzoulis P; Di Maio S; Kattamis C
    Mediterr J Hematol Infect Dis; 2021; 13(1):e2021021. PubMed ID: 33747402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major.
    Karami H; Kosaryan M; Amree AH; Darvishi-Khezri H; Mousavi M
    Clin Pract; 2017 Jan; 7(1):912. PubMed ID: 28243431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mild subclinical hypothyroidism in thalassaemia major: prevalence, multigated radionuclide test, clinical and laboratory long-term follow-up study.
    De Sanctis V; De Sanctis E; Ricchieri P; Gubellini E; Gilli G; Gamberini MR
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():174-80. PubMed ID: 19337174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-Like Growth Factor -1 (IGF-1) and Glucose Dysregulation in Young Adult Patients with β-Thalassemia Major: Causality or Potential Link?
    De Sanctis V; Soliman A; Daar S; Tzoulis P; Yassin MA; Di Maio S; Kattamis C
    Acta Biomed; 2022 Dec; 93(6):e2022331. PubMed ID: 36533767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
    Xia S; Zhang W; Huang L; Jiang H
    PLoS One; 2013; 8(12):e82662. PubMed ID: 24376563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
    Elalfy MS; Saber MM; Adly AA; Ismail EA; Tarif M; Ibrahim F; Elalfy OM
    Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final Height and Endocrine Complications in Patients with β-Thalassemia Intermedia: Our Experience in Non-Transfused Versus Infrequently Transfused Patients and Correlations with Liver Iron Content.
    Yassin MA; Soliman AT; De Sanctis V; Yassin KS; Abdulla MA
    Mediterr J Hematol Infect Dis; 2019; 11(1):e2019026. PubMed ID: 31205630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
    Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.